



PAIRED – PATient Reported Experiences and perceived benefit of treatment with dolutegravir/lamivudine (DTG/3TC): A diverse sample of people with HIV-1 (PWH) reporting high treatment satisfaction, good adherence, and high quality of life

Jihad Slim, MD¹; Andrew P. Brogan, PhD²; Gavin Harper, BA³; Katie Mycock, MChem³; Abigail McMillan, MSc³; Deanna Merrill, PharmD, MBA²; Gustavo Verdier, BSc, BPharm, MBA⁴

¹New York Medical College, Valhalla, NY, USA; ²ViiV Healthcare, Durham, NC, USA; ³Adelphi Real World, Bollington, UK; ⁴ViiV Healthcare, Montreal, Canada

Presenting author:
Andy Brogan
410 Blackwell Street
Durham, NC 27701
+1.619.627.6545
andrew.p.brogan@viiivhealthcare.com



Key Takeaways

- ➡ Satisfaction with DTG/3TC was very high; the proportion of PWH ‘very satisfied’ more than doubled from their previous oral therapy (31% to 68%)
- ➡ The greatest areas of satisfaction were ‘level of control,’ ‘desire to continue present form of treatment,’ and ‘how treatment fits into their lifestyle’
- ➡ According to interpretive scores, PWH had a high (‘good’) quality of life psychologically, socially, and functionally, and a moderate quality of life in terms of health concerns
- ➡ PWH self-reported adherence to once-daily antiretroviral therapy (ART) was very high, and missed doses were a rare occurrence for most
 - Adherence rates for the previous ART regimen were very similar, albeit slightly lower


Introduction

- Despite huge advances in development of highly effective treatment options for PWH, as demonstrated through clinical and real-world data, in order to provide a holistic package of care for PWH, further understanding of PWH’s real-world experience, drivers for treatment choice and satisfaction with their ART are required from an individual’s perspective
- As part of a patient-centric approach, further insight was needed into PWH’s treatment satisfaction with DTG/3TC to meet the ongoing needs of PWH

Methods

- PAIRED comprised a quantitative, cross-sectional survey and in-depth qualitative interviews that assessed PWH ≥18 years switched from a previous ART to DTG/3TC* and currently receiving DTG/3TC for at least 3 months
- This report focuses on the quantitative phase, using a mixed recruitment approach (site-led and community outreach) and validated instruments to assess treatment satisfaction, adherence, and quality of life [HIV-Treatment Satisfaction Questionnaire (HIVTSQs),¹ PoZQoL,² Adelphi Adherence Questionnaire™ (ADAQ)³]
 - Qualitative interview (n=20) findings were reported at AIDS 2024⁴

Figure 1. PAIRED US Study Design



*The commercial name DOVATO was used instead of DTG/3TC in surveys with PWH to aid recall with their treatment

Acknowledgments: This study was funded by ViiV Healthcare.


Results

- PAIRED represented a diverse sample of 474 participants (31% female sex at birth, 48% non-White, and 50% ≥50 years) (Table 1)
- Median time since HIV diagnosis was 13.5 years (IQR: 7.0-23.0) and most (74%) had taken ≥2 previous antiretroviral (ART) regimens (Figure 2)

Table 1. PWH Demographics (n=474)

| Characteristic | Variable |
|---|------------------|
| Age, median years (IQR) | 50.0 (37.0-58.0) |
| ≥50 years | 238 (50.2%) |
| Gender Identity (%) | |
| Cisgender woman | 140 (29.5%) |
| Cisgender man | 312 (65.8%) |
| Transgender woman | 4 (0.8%) |
| Transgender man | 1 (0.2%) |
| Non-binary / Gender queer | 5 (1.1%) |
| A gender identity not listed here | 12 (2.5%) |
| Race | |
| Black or African American | 155 (32.7%) |
| White/Caucasian | 248 (52.3%) |
| Multiracial | 13 (2.7%) |
| Another race not mentioned | 58 (12.2%) |
| Hispanic, Latinx, and/or Spanish Origin | |
| Yes | 160 (33.8%) |
| Sexual Orientation | |
| Homosexual (Gay / Lesbian) | 227 (47.9%) |
| Heterosexual (Straight) | 188 (39.7%) |
| Bisexual / Pansexual | 48 (10.1%) |
| Prefer not to say | 11 (2.3%) |
| Insurance Coverage (n=433) | |
| Medicare | 112 (25.9%) |
| Medicaid (or equivalent in your state) | 122 (28.2%) |
| AIDS Drug Assistance Program (ADAP) | 131 (30.3%) |
| Employer provided / sponsored insurance | 140 (32.3%) |
| Privately arranged insurance | 46 (10.6%) |
| Health insurance exchange plan | 28 (6.5%) |
| Tricare / Veterans health care | 4 (0.9%) |
| Other | 36 (8.3%) |
| Don't know | 9 (2.1%) |
| Length of time person has been diagnosed with HIV-1, median years (IQR) | 13.5 (7.0-23.0) |

Figure 2. Total Number of Prior ART Regimens (n=474)




Switch to DTG/3TC

- The majority switched from either bicitegravir/emtricitabine/tenofovir alafenamide (28%) or abacavir/dolutegravir/lamivudine (28%) to DTG/3TC, and 73% had taken their immediate previous treatment for >12 months
- Majority of participants (62%) had taken DTG/3TC for >12 months. When asked to rank factors influencing switch to DTG/3TC, PWH reported avoidance of side effects and minimizing long-term impact as top 2 factors (Figure 3)

Satisfaction and Quality of Life With DTG/3TC

- Using the HIVTSQs, PWH reported very high satisfaction with DTG/3TC
- Out of a maximum score of 60, the median total HIVTSQs score was 57.0 (IQR: 52.0-60.0)
- Out of a maximum score of 65, participants had an overall median PozQoL score of 47.0 (IQR: 38.5-55.0), indicative of high quality of life

Figure 3. PWH Ranking Factors Influencing Switch to DTG/3TC (n=474)



Treatment Satisfaction and Reducing the Number of Medicines

- PWH reported improved treatment satisfaction with DTG/3TC compared with their previous ART regimen (68% vs 31% very satisfied) (Figure 4) and reducing the number of medicines was extremely or very important to 79% of PWH (Figure 5)

Adherence

- Good adherence was observed using the ADAQ [median ADAQ® 0.4 (IQR: 0.2-0.5); possible scores 0-4 with lower scores indicating greater adherence], with 89% of PWH reporting never or rarely missing a DTG/3TC dose

Driver and Involvement in Switch to DTG/3TC

- Healthcare professionals (HCPs) were the primary driver of conversation that led to DTG/3TC (74%), whereas 24% of PWH requested the switch themselves (Figure 6)
- A majority of PWH and HCPs discussed and made the decision to switch to DTG/3TC together (54%; Figure 6)

Figure 4. PWH-Reported Level of Satisfaction With Previous ART Regimen and DTG/3TC (n=474)




Figure 5. PWH Pre-awareness That DTG/3TC Reduces the Number of Medicines in a Complete Regimen and Importance of Less Medicines to PWH Switching to DTG/3TC (n=474)





Figure 6. PWH-Reported Involvement in Decision to Switch to DTG/3TC and Primary Driver of Conversation That Led to DTG/3TC Switch



Conclusions

- PAIRED represented a diverse real-world sample of PWH switching to DTG/3TC who were highly satisfied with treatment, maintaining good adherence and experiencing high quality of life

References: 1. Woodcock A, Bradley C. Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version. *Value Health*. 2006;9(5):320-333. 2. Brown G, et al. Development and validation of PozQoL: a scale to assess quality of life of PLHIV. *BMC Public Health*. 2018;18(1):527. 3. Bentley S, et al. Qualitative interviews to support development and cognitive debriefing of the Adelphi Adherence Questionnaire (ADAQ®): a patient-reported measure of medication adherence developed for use in a range of diseases, treatment modalities, and countries. *Patient Prefer Adherence*. 2022;16:2579-2592. 4. Slim J, et al. PAIRED - PATient Reported Experiences and perceived benefit of treatment with dolutegravir/lamivudine - qualitative interviews: diverse group of people with HIV-1 (PWH) reflect on life and health. Poster presented at AIDS 2024; July 22-26, 2024; Munich, Germany.



Disclaimer

This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.